Donate

Nurse Education Webinar

Nurse Webinar 5

Webinar 5 will discuss diffuse large B-cell lymphoma.

The presentation will provide a complete overview of diffuse large B-cell lymphoma, from diagnosis, subtypes, staging, prognostic treatment decisions, current standard treatment, new therapies and clinical trials for emerging treatments. The presentation will incorporate case studies to enhance your learning.

Diffuse Large B Cell Lymphoma

Professor Mark Hertzberg, Director, Department of Haematology, Prince of Wales Hospital, Sydney

Professor Hertzberg is the Director of the Clinical Haematology Service at the Prince of Wales Hospital and specialist at the University of NSW in Sydney. He has a particular interest in clinical trials with particular expertise in the management of lymphomas. He is recognised as an international leading expert and has co-authored numerous peer reviewed publications.

Support and information

Patient Online Forum

Find Out More

Lymphoma Nurse Support Phone Line: 1800 953 081
Free Resources for you

Find Out More

Lymphoma Nurse Support Email
nurse@lymphoma.org.au

Sign up to our Newsletter

Back to top
Sign Up
About Us
Lymphoma
Patients
Get Involved
Lymphoma Australia is the only incorporated charity in Australia dedicated to solely providing education, support, awareness and advocacy initiatives for Australians touched by lymphoma and chronic lymphocytic leukemia (CLL).
Copyright © 2025. Lymphoma Australia
Linkedin Spotify
Contact Us
Share This
Cart
Checkout - $0.00
  • 0
  • 1

Contact Lymphoma Australia Today!

Patient Support Hotline

General Enquiries

Please note: Lymphoma Australia staff are only able to reply to emails sent in English language.

For people living in Australia, we can offer a phone translation service. Have your nurse or English speaking relative call us to arrange this.

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.